Acumen Pharmaceuticals Inc. (ABOS)
NASDAQ: ABOSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ABOS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $13.49M
- EPS (TTM)
- -$1.55
- Dividend yield
- None
- 52-week range
- 0.16 – 3.60
- Day range
- 0.1601 – 0.1927
- Volume / Avg
- 2.71M / 2.73M
- Beta
- —
- Shares outstanding
- 72.33M
52-week range
ABOS stock today
On Nov 20, ABOS ended the session at $0.1865, shedding $0.0068 (3.52%), versus the S&P 500's 3.70% decline. Shares are 94.8% below their 52-week high of $3.60, set on Mar 16, 2026 and 16.6% above the 52-week low of $0.16, near the bottom of the past year's range. ABOS is down 91.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 88.1%.
Acumen Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.55), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Acumen Pharmaceuticals
Company profileAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Daniel J. O'Connell M.B.A.
- Headquarters
- Newton, MA
- Employees
- 60
- IPO year
- 2021
- Website
- acumenpharm.com
Financial highlights
Full financialsAcumen Pharmaceuticals reported a net loss of $121.3 million, compared with a loss of $102.3 million a year earlier. Diluted earnings per share came in at -$2.00.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-121.33M | $-102.33M | $-52.37M | $-42.86M | $-100.61M |
| EPS (diluted) | $-2.00 | $-1.71 | $-1.08 | $-1.06 | $-5.02 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$7.60+3975.07%
- Strong buy 0
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 26, 2026
- EPS actual vs est.
- $-0.35 vs $-0.43
- Surprise
- +18.60%
ABOS news
All ABOS news- Acumen Pharmaceuticals, Inc. Announces 90% Workforce Reduction and Terminates Loan Agreement with $23.3 million PayoffNasdaq
- Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Acumen Shares Drop 89% After Sabirnetug Fails Phase 2 Alzheimer's TrialNasdaqABOS, BRK.A
- Acumen Halts Sabirnetug Development After Phase 2 Trial MissNasdaqABOS, HEI.A
- Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary EndpointGlobeNewswire
- Acumen Q3 Loss Narrows; Alzheimer's Trial Results Due November 2026NasdaqABOS, SUN
- Three Movers And A Catalyst: SGRY, XNCR, ORKA Gain As Acumen Nears ALTITUDE-AD ReadoutNasdaqABOS, ORKA, SGRY, XNCR
- Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call TranscriptNasdaqABOS, HEI.A
Acumen Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PLURPluri Inc. | 0.94 | -3.07% | $13.51M | vs ABOS |
| ESLAEstrella Immunopharma Inc. | 0.321 | -5.70% | $14.11M | vs ABOS |
| PASGPassage Bio Inc. | 3.92 | +11.68% | $12.61M | vs ABOS |
| BSEMBioStem Technologies Inc. | 0.6351 | -10.23% | $12.18M | vs ABOS |
| BCDABioCardia Inc. | 0.785 | +1.60% | $11.88M | vs ABOS |
| DYAIDyadic International Inc. | 0.287 | -7.66% | $11.51M | vs ABOS |
| TCRXTScan Therapeutics Inc. | 0.1459 | +2.24% | $9.89M | vs ABOS |
| ATYRaTyr Pharma Inc. | 3.82 | +3.52% | $9.74M | vs ABOS |
Indexes, lists and sector
Acumen Pharmaceuticals stock FAQ
What is Acumen Pharmaceuticals's stock price today?
ABOS last traded at $0.1865 as of Nov 20, 4:00 PM EST, down 3.52% on the day. Prices are delayed at least 15 minutes.
Who is Acumen Pharmaceuticals's CEO?
Mr. Daniel J. O'Connell M.B.A. is the chief executive officer of Acumen Pharmaceuticals Inc., which has about 60 employees.
What is the ABOS 52-week high?
The 52-week high for ABOS is $3.60 and the 52-week low is $0.16. The stock is currently 94.8% below its high.